These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 5710086)

  • 41. Controlled clinical trials with Isoxyl.
    Böszörményi M
    Antibiot Chemother; 1970; 16():124-7. PubMed ID: 4943578
    [No Abstract]   [Full Text] [Related]  

  • 42. Position of cycloserine in the treatment of pulmonary tuberculosis.
    Meyer A; Nadjar G
    Scand J Respir Dis Suppl; 1970; 71():139-43. PubMed ID: 5271974
    [No Abstract]   [Full Text] [Related]  

  • 43. On the treatment of primary tuberculosis in tender age (0-5 years) with resistomycin, cycloserine, and ethionamid.
    Dobrev P; Slaveykova A; Lankova D
    Nauchni Tr Vissh Med Inst Sofiia; 1966; 45(5):37-42. PubMed ID: 4228990
    [No Abstract]   [Full Text] [Related]  

  • 44. Results of combined use of cycloserine in pulmonary tuberculosis.
    Tello F
    Scand J Respir Dis Suppl; 1970; 71():162-7. PubMed ID: 5271979
    [No Abstract]   [Full Text] [Related]  

  • 45. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients.
    Prasad R; Verma SK; Sahai S; Kumar S; Jain A
    Indian J Chest Dis Allied Sci; 2006; 48(3):183-6. PubMed ID: 18610675
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Tuberculostatics of the second order (relay drugs). Their share in combined therapy of pulmonary tuberculosis].
    Naegeli HR
    Schweiz Med Wochenschr; 1966 Apr; 96(15):495-500. PubMed ID: 4293638
    [No Abstract]   [Full Text] [Related]  

  • 47. [Use of 2d series tuberculostatic preparations for pulmonary tuberculosis patients under outpatient conditions].
    Oifabakh MI; Simonian LK
    Probl Tuberk; 1969; 47(11):16-20. PubMed ID: 5369220
    [No Abstract]   [Full Text] [Related]  

  • 48. Results of treatment of patients with pulmonary tuberculous with a combination of cycloserine and other tuberculostatics.
    Raboukhine A
    Scand J Respir Dis Suppl; 1970; 71():155-8. PubMed ID: 5271977
    [No Abstract]   [Full Text] [Related]  

  • 49. Limitations of the clinical activity of cycloserine therapy. Appearance of resistance to cycloserine when used alone and in combination with other drugs.
    Molina C
    Scand J Respir Dis Suppl; 1970; 71():296-305. PubMed ID: 5272000
    [No Abstract]   [Full Text] [Related]  

  • 50. [Attempt at intermittent chemotherapeutic treatment of patients with bacilli resistant to streptomycin and isoniazid (cooperative survey by the antitubercular services of Marrakech, Meknes, Tangiers)].
    Burzoni FJ; Chicou FJ; Durante C; Hetrick G; Ras R
    Rev Tuberc Pneumol (Paris); 1969 Nov; 33(7):975-86. PubMed ID: 5403000
    [No Abstract]   [Full Text] [Related]  

  • 51. A note on the relapse rate over a four-year period in patients with quiescent pulmonary tuberculosis following treatment with reserve regimens.
    Velu S; Sambamoorthy S
    Tubercle; 1968 Dec; 49(4):410-2. PubMed ID: 5716380
    [No Abstract]   [Full Text] [Related]  

  • 52. [Possibilities and limitations of multiple chemoantibiotics in treatment of chronic pulmonary tuberculosis].
    Zanotelli F; Perusi O
    G Ital Mal Torace; 1966; 20(6):365-78. PubMed ID: 5997781
    [No Abstract]   [Full Text] [Related]  

  • 53. [Results of 2 or 3 secondary drug combinations in the retreatment of chronic pulmonary tuberculosis].
    De March Ayuela P; Turell Gumá J
    Rev Clin Esp; 1968 Apr; 109(2):117-26. PubMed ID: 4904020
    [No Abstract]   [Full Text] [Related]  

  • 54. [Tuberculostatic drugs of the second series. (Review of literature)].
    El'nik VI
    Klin Med (Mosk); 1966 Dec; 44(12):19-24. PubMed ID: 4302920
    [No Abstract]   [Full Text] [Related]  

  • 55. Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences.
    de Kantor IN; Barrera L
    Medicina (B Aires); 2007; 67(3):231-7. PubMed ID: 17628909
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A comparison of regimens of ethionamide, pyrazinamide and cycloserine in re-treatment of patients with pulmonary tuberculosis.
    Bignall JR
    Bull Int Union Tuberc; 1968 Dec; 41():175-7. PubMed ID: 4885379
    [No Abstract]   [Full Text] [Related]  

  • 57. [Methods of therapy of patients with chronic destructive pulmonary tuberculosis].
    Utkin VV; Rudoĭ NM
    Klin Med (Mosk); 1968 Dec; 46(12):36-43. PubMed ID: 5737381
    [No Abstract]   [Full Text] [Related]  

  • 58. [Experimental therapy with so-called "minor" tuberculostatics].
    Freerksen E
    Wien Med Wochenschr; 1966 Oct; 116(42):874-7. PubMed ID: 6005730
    [No Abstract]   [Full Text] [Related]  

  • 59. Pulmonary alveolar proteinosis. Treatment in a case complicated by tuberculosis.
    Ramirez J
    Am Rev Respir Dis; 1967 Mar; 95(3):491-5. PubMed ID: 6066626
    [No Abstract]   [Full Text] [Related]  

  • 60. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.
    Kam KM; Yip CW
    Int J Tuberc Lung Dis; 2004 Jun; 8(6):760-6. PubMed ID: 15182147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.